帕金森睡眠障碍的潜在治疗方案:褪黑素
A Potential Treatment for Parkinson’s Sleep Disorder: Melatonin
DOI: 10.12677/ACM.2022.127916, PDF,    科研立项经费支持
作者: 郑文涛:大理大学临床医学院,云南 大理;尹晓玲, 蔡 晖, 赵吉帅, 杨 林*:大理大学第一附属医院临床医学院,云南 大理
关键词: 帕金森病褪黑素睡眠障碍失眠非运动症状发病机制综述Parkinson’s Disease Melatonin Sleep Disorders Insomnia Non-Motor Symptoms Pathogenesis Review
摘要: 帕金森病(Parkinson disease, PD)是一种慢性进行性的中枢神经系统变性疾病,其临床表现包括运动症状,如运动迟缓、姿势和步态异常、肌强直等和非运动症状,如睡眠障碍、感觉障碍等。其中,睡眠障碍在PD患者中因其发病率高、发病类型复杂、有效治疗方案少,严重影响患者的生活质量。褪黑素(MT)是一种由松果体腺分泌的神经激素,其在抗氧化应激、抗炎、保护线粒体以及在改善睡眠障碍、情绪障碍以及增强学习等发面都有发挥着积极作用。通过大量体内外实验,MT被证明是一种安全且耐受性良好的天然药物。目前,MT已被广泛应用于治疗多种神经系统疾病如阿尔茨海默病、帕金森等。本文将从PD的病因及机制、PD的睡眠障碍常见的类型,MT的神经保护作用及其机制,以及MT与PD非运动症状(睡眠障碍)相关性进行概括,重点阐述褪黑素在治疗帕金森病睡眠障碍的潜在可能。
Abstract: Parkinson’s disease (Parkinson disease, PD) is a chronic progressive degenerative disease of the central nervous system. Its clinical manifestations include motor symptoms, such as bradykinesia, abnormal posture and gait, myotonia, and non motor symptoms, such as sleep disorders and sen-sory disorders. Among them, sleep disorders in PD patients have a high incidence rate, complex types of disease and few effective treatment schemes, which seriously affect the quality of life of pa-tients. Melatonin (MT) is a kind of neurohormone secreted by pineal gland. It plays an active role in anti oxidative stress, anti-inflammatory, mitochondrial protection, sleep disorders, mood disorders and learning enhancement. Through a large number of in vivo and in vitro experiments, MT has been proved to be a safe and well tolerated natural drug. At present, MT has been widely used to treat a variety of nervous system diseases, such as Alzheimer’s disease, Parkinson’s disease and so on. This article will summarize the etiology and mechanism of PD, the common types of sleep disor-ders in PD, the neuroprotective effect and mechanism of MT, and the correlation between MT and PD non motor symptoms (sleep disorders), focusing on the potential of melatonin in the treatment of sleep disorders in Parkinson’s disease.
文章引用:郑文涛, 尹晓玲, 蔡晖, 赵吉帅, 杨林. 帕金森睡眠障碍的潜在治疗方案:褪黑素[J]. 临床医学进展, 2022, 12(7): 6345-6352. https://doi.org/10.12677/ACM.2022.127916

参考文献

[1] Uysal, H.A., Tiftikcioğlu, B.I., Öcek, L., et al. (2019) Serum Levels of Melatonin and Sleep Evaluation Scales in the Di-agnosis of Sleep Disorders in Patients with Idiopathic Parkinson’s Disease. Noro Psikiyatri Arsivi, 56, 264-268.
[2] Djeridane, Y., Vivien-Roels, B., Simonneaux, V., et al. (1998) Evidence for Melatonin Synthesis in Ro-dent Harderian Gland: A Dynamic in Vitro Study. Journal of Pineal Research, 25, 54-64. [Google Scholar] [CrossRef
[3] Reiter, R.J., Tan, D.X., Kim, S.J., et al. (2014) Delivery of Pineal Melatonin to the Brain and SCN: Role of Canaliculi, Cerebrospinal Fluid, Tanycytes and Virchow-Robin Peri-vascular Spaces. Brain Structure and Function, 219, 1873- 1887. [Google Scholar] [CrossRef] [PubMed]
[4] Bloem, B.R., Okun, M.S. and Klein, C. (2021) Parkinson’s Dis-ease. The Lancet, 397, 2284-2303. [Google Scholar] [CrossRef
[5] Pan, P.Y. and Yue, Z. (2014) Genetic Causes of Parkin-son’s Disease and Their Links to Autophagy Regulation. Parkinsonism & Related Disorders, 20, S154-S157. [Google Scholar] [CrossRef
[6] Virameteekul, S,, Phokaewvarangkul, O. and Bhidayasiri, R. (2021) Profiling the Most Elderly Parkinson’s Disease Patients: Does Age or Disease Duration Matter? PLOS ONE, 16, e0261302. [Google Scholar] [CrossRef] [PubMed]
[7] Shukla, P., Rao, G.M., Pandey, G., et al. (2014) Therapeutic Interventions in Sepsis: Current and Anticipated Pharmacological Agents. British Journal of Pharmacology, 171, 5011-5031. [Google Scholar] [CrossRef] [PubMed]
[8] Mukoyama, M., Nakao, K., Saito, Y., et al. (1990) Human Brain Natriuretic Peptide, a Novel Cardiac Hormone. The Lancet, 335, 801-802. [Google Scholar] [CrossRef
[9] Bjorklund, G., Stejskal, V., Urbina, M.A., et al. (2018) Met-als and Parkinson’s Disease: Mechanisms and Biochemical Processes. Current Medicinal Chemistry, 25, 2198-2214. [Google Scholar] [CrossRef] [PubMed]
[10] Marras, C., Canning, C.G. and Goldman, S.M. (2019) Environment, Lifestyle, and Parkinson’s Disease: Implications for Prevention in the Next Decade. Movement Disorders, 34, 801-811. [Google Scholar] [CrossRef] [PubMed]
[11] Deng, H., Wang, P. and Jankovic, J. (2018) The Genetics of Parkinson Disease. Ageing Research Reviews, 42, 72-85. [Google Scholar] [CrossRef] [PubMed]
[12] Cherian, A. and Divya, K.P. (2020) Genetics of Parkinson’s Dis-ease. Acta Neurologica Belgica, 120, 1297-1305. [Google Scholar] [CrossRef] [PubMed]
[13] Riboldi, G.M. and Di Fonzo, A.B. (2019) GBA, Gaucher Dis-ease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells, 8, 364. [Google Scholar] [CrossRef] [PubMed]
[14] Simon, D.K., Tanner, C.M. and Brundin, P. (2020) Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clinics in Geriatric Medicine, 36, 1-12. [Google Scholar] [CrossRef] [PubMed]
[15] Liu, M., Luo, Y.J., Gu, H.Y., et al. (2021) Sex and On-set-Age-Related Features of Excessive Daytime Sleepiness and Night-Time Sleep in Patients with Parkinson’s Disease. BMC Neurology, 21, Article No. 165. [Google Scholar] [CrossRef] [PubMed]
[16] Iijima, M., Osawa, M., Yasuda, S., et al. (2021) Association between Excessive Daytime Sleepiness and the Cholinergic Ascending Reticular System in Parkinson’s Disease. Neuro-degenerative Diseases, 21, 48-54. [Google Scholar] [CrossRef] [PubMed]
[17] Feng, F., Cai, Y., Hou, Y., et al. (2021) Excessive Daytime Sleepiness in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Parkinsonism & Related Disorders, 85, 133-140. [Google Scholar] [CrossRef] [PubMed]
[18] Knie, B., Mitra, M.T., Logishetty, K., et al. (2011) Excessive Daytime Sleepiness in Patients with Parkinson’s Disease. CNS Drugs, 25, 203-212. [Google Scholar] [CrossRef] [PubMed]
[19] Gallazzi, M., Mauri, M., Bianchi, M.L., et al. (2021) Selegiline Reduces Daytime Sleepiness in Patients with Parkinson’s Disease. Brain and Behavior, 11, e01880. [Google Scholar] [CrossRef] [PubMed]
[20] Hu, M.T. (2020) REM Sleep Behavior Disorder (RBD). Neurobiology of Disease, 143, Article ID: 104996. [Google Scholar] [CrossRef] [PubMed]
[21] Xie, C., Zhu, M. and Hu, Y. (2021) Risk Stratification for REM Sleep Behavior Disorder in Patients with Parkinson’s Disease: A PRISMA-Compliant Meta-Analysis and Systematic Review. Clinical Neurology and Neurosurgery, 202, Article ID: 106484. [Google Scholar] [CrossRef] [PubMed]
[22] Jiang, H., Huang, J., Shen, Y., et al. (2017) RBD and Neuro-degenerative Diseases. Molecular Neurobiology, 54, 2997- 3006. [Google Scholar] [CrossRef] [PubMed]
[23] Jozwiak, N., Postuma, R.B., Montplaisir, J., et al. (2017) REM Sleep Behavior Disorder and Cognitive Impairment in Parkinson’s Disease. Sleep, 40, zsx101. [Google Scholar] [CrossRef] [PubMed]
[24] Shin, C., Park, H., Lee, W.W., et al. (2019) Clonazepam for Probable REM Sleep Behavior Disorder in Parkinson’s Disease: A Randomized Placebo-Controlled Trial. Journal of the Neuro-logical Sciences, 401, 81-86. [Google Scholar] [CrossRef] [PubMed]
[25] Yang, X., Liu, B., Shen, H., et al. (2018) Prevalence of Restless Legs Syndrome in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Observational Studies. Sleep Medi-cine, 43, 40-46. [Google Scholar] [CrossRef] [PubMed]
[26] Marques, A., Figorilli, M., Lambert, C., et al. (2021) The Urge to Move: From Restless Legs Syndrome to Impulse Control Disorders in Parkinson’s Disease. Journal of Sleep Research, 30, e13127. [Google Scholar] [CrossRef] [PubMed]
[27] De Rosa, A., Guacci, A., Peluso, S., et al. (2013) A Case of Restless Leg Syndrome in a Family with LRRK2 Gene Mutation. International Journal of Neuroscience, 123, 283-285. [Google Scholar] [CrossRef] [PubMed]
[28] Piao, Y.S., Lian, T.H., Hu, Y., et al. (2017) Restless Legs Syndrome in Parkinson Disease: Clinical Characteristics, Abnormal Iron Metabolism and Altered Neurotransmitters. Scientific Reports, 7, Article No. 10547. [Google Scholar] [CrossRef] [PubMed]
[29] Sobreira-Neto, M.A., Pena-Pereira, M.A., Sobreira, E.S.T., et al. (2021) Is Restless Legs Syndrome in Parkinson Disease Patients Associated with Any Specific Factor? Arquivos de Neuro-Psiquiatria, 79, 38-43. [Google Scholar] [CrossRef] [PubMed]
[30] Esposito, E. and Cuzzocrea, S. (2010) Antiinflammatory Activity of Melatonin in Central Nervous System. Current Neuropharmacology, 8, 228-242. [Google Scholar] [CrossRef] [PubMed]
[31] Cardinali, D.P., Golombek, D.A., Rosenstein, R.E., et al. (1997) Melatonin Site and Mechanism of Action: Single or Multiple? Journal of Pineal Research, 23, 32-39. [Google Scholar] [CrossRef
[32] Leclerc, V., Ettaoussi, M., Rami, M., et al. (2011) De-sign and Synthesis of Naphthalenic Derivatives as New Ligands at the Melatonin Binding Site MT3. European Journal of Medicinal Chemistry, 46, 1622-1629. [Google Scholar] [CrossRef] [PubMed]
[33] Tan, D.X., Reiter, R.J., Manchester, L.C., et al. (2002) Chemical and Physical Properties and Potential Mechanisms: Melatonin as a Broad Spectrum Antioxidant and Free Radical Scav-enger. Current Topics in Medicinal Chemistry, 2, 181-197. [Google Scholar] [CrossRef] [PubMed]
[34] Reiter, R.J., Mayo, J.C., Tan, D.X., et al. (2016) Melatonin as an Antioxidant: Under Promises But over Delivers. Journal of Pineal Research, 61, 253-278. [Google Scholar] [CrossRef] [PubMed]
[35] Cui, L., Xu, F., Jiang, Z., et al. (2021) Mela-tonin Regulates Proliferation and Apoptosis of Endometrial Stromal Cells via MT1. Acta Biochimica et Biophysica Sinica (Shanghai), 53, 1333-1341. [Google Scholar] [CrossRef] [PubMed]
[36] Feng, T.Y., Li, Q., Ren, F., et al. (2020) Melatonin Protects Goat Spermatogonial Stem Cells against Oxidative Damage during Cryopreservation by Improving Antioxidant Capacity and Inhibiting Mitochondrial Apoptosis Pathway. Oxidative Medicine and Cellular Longevity, 2020, Article ID: 5954635. [Google Scholar] [CrossRef] [PubMed]
[37] Tamtaji, O.R., Reiter, R.J., Alipoor, R., et al. (2020) Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms. Cell Molecular Neurobiology, 40, 15-23. [Google Scholar] [CrossRef] [PubMed]
[38] Niranjan, R., Nath, C. and Shukla, R. (2010) The Mechanism of Action of MPTP-Induced Neuroinflammation and Its Modulation by Melatonin in Rat Astrocytoma Cells, C6. Free Rad-ical Research, 44, 1304-1316. [Google Scholar] [CrossRef] [PubMed]
[39] Hardeland, R. (2018) Melatonin and Inflammation-Story of a Double-Edged Blade. Journal of Pineal Research, 65, e12525. [Google Scholar] [CrossRef] [PubMed]
[40] Bilici, D., Akpinar, E. and Kiziltunç, A. (2002) Protective Effect of Melatonin in Carrageenan-Induced Acute Local Inflammation. Pharmacological Research, 46, 133-139. [Google Scholar] [CrossRef
[41] Tholfsen, L.K., Larsen, J.P., Schulz, J., et al. (2015) Development of Excessive Daytime Sleepiness in Early Parkinson Disease. Neu-rology, 85, 162-168. [Google Scholar] [CrossRef
[42] Videnovic, A., Noble, C., Reid, K.J., et al. (2014) Circadian Melatonin Rhythm and Excessive Daytime Sleepiness in Parkinson Disease. JAMA Neurology, 71, 463-469. [Google Scholar] [CrossRef] [PubMed]
[43] Vecchierini, M.F., Kilic-Huck, U. and Quera-Salva, M.A. (2021) Melatonin (MEL) and Its Use in Neurological Diseases and Insomnia: Recommendations of the French Medical and Research Sleep Society (SFRMS). Revue Neurologique (Paris), 177, 245-259. [Google Scholar] [CrossRef] [PubMed]
[44] Boeve, B.F., Silber, M.H. and Ferman, T.J. (2003) Melatonin for Treatment of REM Sleep Behavior Disorder in Neurologic Disorders: Results in 14 Patients. Sleep Medicine, 4, 281-284. [Google Scholar] [CrossRef